The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2017 / Apr / Making the Media of the Future – Today
Manufacture Bioprocessing Biopharma Sponsored

Making the Media of the Future – Today

Biopharma manufacturing continues to advance and the demand for new innovations, such as more efficient cell culture media, is constant.Biopharma manufacturing continues to advance and the demand for new innovations, such as more efficient cell culture media, is constant.

04/21/2017 1 min read

Share

In previous articles in this series, we heard about intensified perfusion systems from Delia Lyons (1), and about high-density cryopreservation from Jochen Sieck (2). Now, Lyons is joined by Jeremiah Riesberg (Senior Scientist, Perfusion Medium Development, Millipore Sigma, USA) to discuss a novel culture medium. The product, currently in beta testing with chosen clients, has been designed for the most challenging of applications – intensified perfusion at steady state – but is also applicable to a range of other processes.

Figure 1: Final medium (M3) could maintain a target cell density with a 40pL/cell/d with a 50 percent increase in specific productivity compared to prototype M1.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. D Lyons, “An Intense Focus on Perfusion”, The Medicine Maker, 27 (2017). Available at: http://bit.ly/2mF5Dqp. JB Sieck, “Freezing Down Time in Bioprocessing”, The Medicine Maker, 28 (2017). Available at: http://bit.ly/2nK7wzD.

Recommended

Related Content

Video: Sitting Down With… Delara Motlagh
Cell & Gene Bioprocessing Outsourcing
Video: Sitting Down With… Delara Motlagh

November 13, 2026

1 min read

Fujifilm Cellular Dynamics’ Delara Motlagh discusses her path into cell and gene therapy, the challenges of scaling manufacturing, and the potential of iPSC technologies

Lonza to Acquire Five US CDMO Sites from Merck KGaA
Biopharma Bioprocessing Industry News
Lonza to Acquire Five US CDMO Sites from Merck KGaA

November 11, 2026

2 min read

The deal adds viral vector, bioconjugation, payload-linker, and advanced drug-delivery capabilities to Lonza’s manufacturing network

Is Pharma Building the Right Facilities for Future Biologics?
Bioprocessing Facilities & Equipment Biopharma
Is Pharma Building the Right Facilities for Future Biologics?

November 9, 2026

5 min read

As biologics portfolios expand and average product volumes fall, Miriam Monge asks whether today’s major manufacturing investments offer the flexibility tomorrow’s market will require

What Will It Take to Control Continuous Biomanufacturing
Bioprocessing Biopharma Research News
What Will It Take to Control Continuous Biomanufacturing?

November 2, 2026

2 min read

Review examines how PAT, model-based control, reinforcement learning, and digital twins could maintain product quality from perfusion culture through downstream purification

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: